Schrodinger(US:SDGR)2025-06-18 17:00Financial Data and Key Metrics Changes - The meeting confirmed a quorum with 52,556,775 shares of common stock and 9,164,193 shares of limited common stock present, representing a majority voting power [7][14]. Business Line Data and Key Metrics Changes - The company has around 1,800 customers and engages in collaborations in drug design and materials design, indicating a robust business model supported by a differentiated computational platform [16][17]. Market Data and Key Metrics Changes - The company is focused on advancing its proprietary clinical programs, with recent presentations of phase one data for its MOLT1 inhibitor, showing a favorable safety profile and preliminary efficacy [21][22]. Company Strategy and Development Direction - The strategic priorities include increasing customer adoption of the computational platform, delivering major enhancements to existing technologies, and advancing proprietary discovery and development programs [24][25]. Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about upcoming discussions with the FDA regarding the recommended phase two dose for their clinical programs, indicating a positive outlook for future developments [21][22]. Other Important Information - The company has achieved significant milestones in its strategic priorities, including presenting clinical data for its proprietary programs and continuing to enhance its technology offerings [23][24]. Q&A Session Summary Question: Are there any questions from stockholders? - There were no questions submitted during the meeting [11][25].